Drug developer Watson said that the Food and Drug Administration approved its generic version of Dey LP's respiratory condition treatment DuoNeb.Duoneb is a combination of two bronchodilators, Albuterol Sulphate and Ipratropium Bromide. It is used to treat symptoms (ie, bronchospasms) in patients with lung disease (ie, chronic obstructive pulmonary disease or COPD). It is commonly administered using a nebulizer.
Duoneb is marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb®. It is available as a fluid (for use with a nebulizer).
Thursday, 3 January 2008
FDA approves Watson respiratory drug
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment